Kornimate/medical-research-clean huggingface dataset:
health literacy as a mediator between gender, illness identity, and self-efficacy

Conditions: Cardiac Diseases

Summary: the goal of this observational study is to understand the role of health literacy in shaping the relationship between gender differences, illness identity, and self-efficacy in geriatric patients with cardiac diseases. the main question it aims to answer is: does health literacy mediate the relationship between gender, illness identity, and self-efficacy in elderly cardiac patients? participants with diagnosed cardiac conditions, will complete online surveys assessing their health literacy, illness identity, and self-efficacy over a one-year period. structural equation modeling (sem) will be used to analyze the relationships among these variables.


Eligibility criteria:
inclusion criteria: * adults aged 30 years or older. * diagnosed with a cardiac disease (e.g., heart failure, coronary artery disease, arrhythmia). * able to provide informed consent. * sufficient health literacy to complete surveys in the study language. * currently under regular medical care for their cardiac condition. exclusion criteria: * individuals with a cognitive impairment or diagnosis of dementia that could interfere with survey participation. * patients with co-morbid terminal illnesses that significantly impact life expectancy (e.g., advanced cancer).

Keywords: health literacy gender differences
optical surface monitoring technology-guided large-segment radiotherapy for breast cancer

Conditions: Breast Cancer; Optical Surface Monitoring Technology; Large-segment Radiotherapy

Summary: this study is a single-center,blinded, efficacious, phase iii randomized clinical trial initiated by investigators. the primary objective is to investigate the use of surface guided radiation therapy (sgrt) in combination with deep inspiration breath hold (dibh) technique for left breast cancer treatment, compared to traditional laser alignment with free breathing treatment. this approach offers superior positioning accuracy and improved heart protection without any increase in radiation or adverse reactions.

this is an investigator-initiated blinded, efficacious, phase iii randomized clinical trial study. the study hypothesis is that the use of surface guided radiation therapy (sgrt) in combination with the deep inspiration breath hold (dibh) technique for left breast cancer treatment can improve positioning accuracy and heart protection without any increase in radiation or adverse reactions. the primary endpoint of this study is the accuracy of the treatment location and incidence of patient coronary events/myocardial perfusion decline.

Eligibility criteria:
inclusion criteria: 1. patients who have undergone breast-conserving surgery or modified radical mastectomy for left breast cancer; 2. planned whole-breast ± supraclavicular region, chest wall ± supraclavicular region radiotherapy; 3. able to perform deep inspiration breath-hold technique with breath-holding time \>35s and can repeat it continuously for more than 6 times; 4. patients who have not received neoadjuvant chemotherapy or breast reconstruction surgery; 5. no active heart disease, myocardial infarction, congestive heart failure or other cardiac diseases at baseline; 6. patients are fully voluntary and able to sign the informed consent form 30 days before enrollment. exclusion criteria: 1. bilateral breast cancer; 2. no pathological diagnosis; 3. remote metastasis; 4. receiving neoadjuvant chemotherapy or breast reconstruction; 5. have received mediastinal radiotherapy in the past; 6. previous history of abdominal or pelvic radiotherapy; 7. previous or secondary primary malignant tumor; 8. serious cardiac insufficiency; myocardial infarction or uncorrected unstable arrhythmia or uncorrected unstable angina pectoris occurred in the last 3 months; pericardial disease.

Keywords: breast cancer optical surface monitoring technology large-segment radiotherapy
immune modulation by parenteral lipids

Conditions: Infections; Total Parenteral Nutrition

Summary: immune modulating properties of parenteral lipid emulsions seem to contribute to the increased risk for infections which remains associated with the use of total parenteral nutrition. emulsions based on soy bean oil (so) are the oldest and still most widely used lipid source in tpn formulations but their high content of omega-6 polyunsaturated fatty acids (pufas) may be a drawback. fish oil-based lipid emulsions (fo), rich in omega-3 pufas, has been approved for parenteral nutrition in many countries. mainly retrospective studies on clinical outcomes in septic and postoperative patients have suggested clinical benefits with the inclusion of fo in parenteral nutrition regimens. the exact mechanisms behind the beneficial immunological effects of parenteral fo have, however, not yet been elucidated. objective: to evaluate the effects of intravenous infusion of a fo-based lipid emulsion and a so-based emulsion on immune function as evidenced by effects on peripheral blood leukocyte counts and functions and on the susceptibility to oxidative stress. study design: randomized placebo controlled cross-over pilot study with healthy volunteers.


Eligibility criteria:
inclusion criteria: * adult (\>18 yrs of age) * healthy * willingness to give written informed consent exclusion criteria: * smoking \> 5 cigarettes/day * diet with \> 2 portions of fatty fish per day * use of oral fish oil or vitamin substrates * history of metabolic disorder (especially diabetes or lipid disorders) * history of allergic, inflammatory of immunological disease * history of pulmonary, cardiovascular, renal or hematological disease * medication use

Keywords: total parenteral nutrition infections infectious complications related to parenteral nutrition
lean body mass and side effects in patients with lymphoma

Conditions: Malignant Lymphoma

Summary: the primary purpose is to investigate the relationship between the dose of chemotherapeutic agents per kilogram of lean body mass (lbm) and the development of side effects induced by chemotherapy in patients with lymphoma. secondarily, the maximum tolerable dose of chemotherapeutics (mtd), patients' quality of life (qol), nutritional status and physical activity during the course of treatment are estimated.


Eligibility criteria:
inclusion criteria: * patients receiving myelosuppressive treatment for malignant lymphoma assessed by the investigator. * legal of age exclusion criteria: * ecog performance status ≥2 * people who cannot speak and understand danish * pregnant and breastfeeding * dementia

Keywords: lymphoma body composition lean body mass chemotherapy quality of life (qol) nutritional status physical activity
detection of hepatocellular carcinoma (hcc) with octanoate breath id test compared to mri

Conditions: Chronic Liver Disease; Hepatocellular Carcinoma (HCC)

Summary: the exalenz clinical investigation is a multicenter, non-randomized, study of the ¹³c-octanoate breath test (obt). the present study is a feasibility trial, which aims to evaluate the capability of the obt measurement to differentiate between presence and absence of hcc determined by magnetic resonance imaging (mri) in patients with chronic liver disease.

the octanoate breath test (obt) developed by exalenz is performed by the breathid system consists of the breathid device and a test kit containing a nasal cannula, a calibration gas container and a non-radioactive isotope ¹³c- octanoate solution, and measures and computes the ratio between ¹³co2 and 12co2 in the patient's exhaled breath. this study's aim is to provide data on this novel system to dynamically and accurately assess liver function at the bed side. it is hoped that the system will provide prognostic information faster than is achieved at present with traditional methods. it is hypothesized that in the future the obt may have an impact on decision making and clinical practice in this group of hcc patients, allowing a greater chance for proper management and hence survival.

Eligibility criteria:
inclusion criteria: * any patients with chronic liver disease at risk for hcc. * age \> 18 years. * patient has an mri result (positive or negative for hcc) up to 3 months prior to recruitment or will be scheduled for an mri during the trial period. * patient is naïve to any hcc treatment. exclusion criteria: * underwent any rfa or tace or oral hcc treatments. * portal vein thrombosis. * prior tips placement. * severe congestive heart failure (lvef on echocardiogram \< 20%). * severe pulmonary hypertension (by echocardiogram, pas \>45 mmhg). * uncontrolled diabetes mellitus (hba1c \>9.5%). * any autoimmune disorder, which is currently being treated with prednisone or any other immune suppressive medication. * previous surgical bypass surgery for morbid obesity (bmi \>45). * extensive small bowel resection. * patients currently receiving total parenteral nutrition if they have contraindications to oral drugs. * women who are pregnant or breast feeding. * patients with an acute current exacerbation of chronic obstructive pulmonary disease or bronchial asthma. * patient has taken drugs that can interfere with octanoate metabolism or can also cause nafld independent of the metabolic syndrome, including: corticosteroids, amiodarone, tetracycline, valproic acid, methotrexate, stavudine, zidovudine. * patient, based on the opinion of the investigator, should not be enrolled into this study. * patient is unable or unwilling to sign informed consent. * patients that are participating in other clinical trials evaluating experimental treatments or procedures

Keywords: hcc hepatocellular carcinoma obt octanoate breath test
effect of bimekizumab in patients with psoriasis vulgaris and active psoriatic arthritis

Conditions: Psoriasis Vulgaris; Active Psoriatic Arthritis

Summary: this is an open-label study to evaluate the effects of bimekizumab in patients with psoriasis vulgaris and who also have active psoriatic arthritis (psa).

this study is being conducted to evaluate the effects of bimekizumab administered subcutaneously (sc) to patients with psoriasis vulgaris and who also have active psa who have an inadequate skin response to anti-interleukin (il)23 therapy. approximately 20 adult subjects with psoriasis vulgaris and active psa who have an inadequate skin response to anti-il23 will receive bimekizumab 320 mg solution administered sc every 4 weeks for 16 weeks.

Eligibility criteria:
inclusion criteria: 1. male or female patient 18 years of age or older at the time of consent. 2. patient with a history of psoriasis vulgaris and psa (as determined by the investigator) for ≥ 6 months prior to the screening visit. 3. patient with moderate-to-severe psoriasis vulgaris before initiating treatment with an anti-il23 agent. 4. patient with an inadequate skin response to at least 12 weeks treatment with an anti-il23 agent for the treatment of psoriasis vulgaris as defined by a pga ≥ 2 and plaque psoriasis covering ≥ 1% of total bsa (excluding palms and soles) at the screening and day 1 visits. 5. patient with active psa as defined by ≥ 1 joint that is tender (tjc68) and/or swollen (sjc66) at day 1. exclusion criteria: 1. female who is breastfeeding, pregnant, or who is planning to become pregnant during the study or within 4 months after the last study product administration. 2. patient with evidence of erythrodermic, pustular, predominantly guttate psoriasis, or drug-induced psoriasis. 3. patient with any known clinically significant medical condition or presence of a skin or rheumatologic disease that would, in the opinion of the investigator, put the patient at undue risk or interfere with the interpretation of study results. 4. patient who plans to receive a live or live-attenuated vaccine during the study and up to 4 weeks or 5 half-lives (of the study product), whichever is longer, after the last study product administration. 5. patient with an active infection (except common cold) that would place them at increased risk, a recent serious infection, or a history of opportunistic, recurrent, or chronic infections. 6. patient with a diagnosis of inflammatory bowel disease (crohn's disease or ulcerative colitis). 7. patient with known or suspected hypersensitivity to bimekizumab or any component of the investigational product, including any nonmedicinal ingredient, or component of the container. 8. patient who has received any marketed or investigational biological agent, except anti-il23 agents, within 12 weeks or 5 half-lives (whichever is longer) prior to day 1. 9. patient who has received treatment with bimekizumab prior to day 1.

Keywords: plaque psoriasis systemic therapy psoriasis vulgaris arthritic psoriasis bimekizumab
pulsed radiofrequency ablation and steroid injections for the treatment of meralgia paresthetica

Conditions: Meralgia Paresthetica

Summary: meralgia paresthetica (mp) is a mononeuropathy of the lateral femoral cutaneous nerve (lfcn), characterized by pain, numbness, hyperesthesia, or hypoesthesia, especially in the anterolateral thigh where the nerve has a sensory distribution. thelfcn passes between the psoas and quadratus lumborum muscles in the iliac fossa and enters the thigh under the inguinal ligament by passing through the anterior superior iliac spine over the iliacus muscle. it superficially spreads over the sartorius muscle and receives sensation in the anterolateral thigh. ultrasonography (us) is frequently used by physiatrists in the diagnosis and interventional treatment of musculoskeletal diseases. mp is usually diagnosed with clinical symptoms such as burning, tingling, pain, and dysesthesia in the anterolateral thigh. electromyography, us, and magnetic resonance imaging are helpful in diagnosis. us is an easy-to-apply, inexpensive method in daily practice, providing great comfort to clinicians in determining etiology and differential diagnosis. treatment may include patient education, avoiding tight belts, losing weight, conservative treatment methods, use of non-steroidal anti-inflammatory drugs, local anesthetic and/or steroid injections, surgical neurectomy, neurolysis or transpositions. however, in recent years, there have been case series showing that radiofrequency ablation (rf) can also be applied. the aim of this study is to compare the effectiveness of rf ablation of the lateral femoral cutaneous nerve with steroid injection in patients with clinically diagnosed mp and confirmed by us.


Eligibility criteria:
inclusion criteria: * patients with numbness, tingling and pain in the anterolateral thigh region * patients with edematous lfcn observed on ultrasound and diagnosed with mp and with complaints resistant to conservative treatment * being literate exclusion criteria: * history of lumbar discopathy or history of discopathy surgery * cardiac pacemaker * history of bilateral hip, knee, foot and lumbar region fractures * history of previous hip and knee surgery * fixed joint contracture in the lower extremity * history of malignancy and chemotherapy or radiotherapy * presence of any neuromuscular disease * progressive or non-progressive central and peripheral nervous system disease * patients in pregnancy and lactation * bleeding diathesis, inr\>1.2 * uncontrolled diabetes or other serious comorbidities * allergy to drugs or materials used * local infections or sepsis

Keywords: meralgia paresthetica pulsed radiofrequency ablation lateral femoral cutaneous nerve
reducing sedentary time in rheumatoid arthritis: the take a stand for health study

Conditions: Rheumatoid Arthritis

Summary: this research program aims to comprehensively investigate the clinical, physiological, metabolic, and molecular effects of reducing sedentary behavior in rheumatoid arthritis. to this aim, we will conduct a 4-month parallel-group randomized controlled trial aiming to investigate the feasibility and efficacy of a newly developed personalized intervention focused on replacing sedentary time with light-(or very light-) intensity physical activity in rheumatoid arthritis. additionally, a sub-sample of patients will complete a randomised cross-over study aiming to unravel potential mechanisms underlying the metabolic, physiological and molecular effects of breaking up sedentary time with light-intensity physical activity versus carrying out the minimum amount of daily exercise at once and then remaining sedentary versus simply remaining sedentary throughout all sessions, in a well-controlled laboratorial condition.


Eligibility criteria:
inclusion criteria: * post-menopausal women diagnosed with rheumatoid arthritis exclusion criteria: * any physical disabilities that preclude physical exercise testing * participation in structured exercise training programs within the last 12 months * unstable dose of disease modifying drugs, including biological therapy, in the last 3 months prior to and during the study
comparison of a new patient warming system using a polymer conductive warming under-body and upper-body blanket with forced air warming

Conditions: Hypothermia

Summary: intraoperative active warming is usually performed by skin warming. there are several forced-air systems on the market; forced air warming is generally described as the most effective yet feasible method of patient warming. augustine biomedical (eden prairie, mn, usa) recently introduced a new patient warming system named "hot dog" with an active polymer warming upper-body blanket and a new under-body warming mattress. the polymer-heating devices consist of an electronic regulator and the polymer blankets, which are covered with a washable fabric. conventional mains power the system. the manufacturer claims, that the new system "hot dog" (with combination of under body and upper body warming) is as effective as forced air warming, while not having any disadvantages of the forced air system, like: airborne infection, noise, high power consumption and hard-to-clean hose. the investigators will compare the new hot dog patient warming device combination (under body + upper body) with the established warming system, which blows warm air via a mattress over the body of the patients).


Eligibility criteria:
inclusion criteria: * the investigators will study 40 patients (18-90 years) undergoing elective orthopedic lower limb surgery at the trauma surgery unit. the patients must have normal weight (20-30 bmi), the duration of surgery should last between 2 - 3 hours. exclusion criteria: * there will be no other exclusion criteria (except severe peripheral arterial disease in the warmed extremity), as forced air patient warming is routinely used for all patients during this procedure.

Keywords: perioperative hypothermia prevention accidental perioperative hypothermia
effectiveness of anthroposophic speech therapy in patients with asthma

Conditions: Asthma

Summary: anthroposophic therapeutic speech is a complementary method that indirectly influences breathing and uses specific vowels, consonants, syllables and metres depending on the indication. the aim of this study is to test the effectiveness of anthroposophic therapeutic speech in patients with asthma regarding clinical and physiological parameters, asthma control and quality of life.

background breathing retraining techniques receive increased attention in the management of asthma, since the evidence for safety and usefulness of such procedures is growing. physiotherapist-guided breathing programs, such as the papworth method and the buteyko method, are most systematically investigated and hence yield the best evidence of effectiveness. active breathing modulation techniques are frequently assigned to complementary and alternative medicine cam, comprising of a variety of systems and modalities other than the politically dominant healthcare system. however, patients may take a different perspective, since the prevalence of cam use in the treatment of asthma is at a level of 20-30% among adults and 50 - 60% for children, even if rigorous estimates are being applied. anthroposophic therapeutic speech applies sounds and syllabic rhythm, e.g. the hexameter, for improving articulation, breathing and cardiorespiratory interaction. the method has been used for many years as a breathing retraining method for asthma in all settings. this study is the first to systematically investigate the effects of ats in asthma patients in a real-life outpatient setting. objective the following hypotheses are tested: i) anthroposophic therapeutic speech improves relevant parameters of pulmonary function in patients with asthma. ii) anthroposophic therapeutic speech reduces the use of as-needed medication in patients with asthma. iii) anthroposophic therapeutic speech improves asthma control and quality of life in patients with asthma. methods the study is a randomised, controlled, multicentre, 2-period cross-over clinical trial conducted at 3 centres in switzerland and germany. participants are randomly assigned in a 1:1 allocation ratio to either firstly receive 11 speech therapy sessions or to wait (control), followed by a cross-over to the other group.

Eligibility criteria:
inclusion criteria: * signed informed consent * age ≥ 12 years * asthma ≥ 1 year * inhaling β2 agonist ≥ once weekly exclusion criteria * not willing to perform therapy actively * insufficient general condition for active therapy * copd * coronary heart disease * oral corticosteroids * pregnancy
banxiaxiexin decoction combined with vonoprazan-amoxicillin dual therapy in h.pylori eradication

Conditions: Helicobacter Pylori Infection

Summary: vonoprazan and high-dose amoxicillin dual therapy was used as a control group to evaluate the clinical effiency and safety of banxiaxiexin decoction combined with vonoprazan and high-dose amoxicillin dual therapy in the treatment of helicobacter pylori infection complicated with functional dyspepsia,through a randomized controlled trail.

helicobacter pylori（h.pylori）is a gastric pathogen, related to various gastrointestinal disorders. it's now a consensus of experts that h.pylori infection should be treated once it is recognized. vonoprazan and high-dose amoxicillin dual therapy is a potential h.pylori eradication regimen. it provides a satisfactory eradication rate of 90%. nevertheless,it has certain limitations, including a series of problems such as low eradication rate and more side effects of eradication in recurrent patients. the main side effects of the dual therapy for eradication are related symptoms of gastric motility deficiency and indigestion, such as bloating, abdominal pain, belching, acid reflux, etc. combining traditional chinese medicine may be one of the effective ways to solve the above problems.this study aims to compare the efficacy of banxiaxiexin decoction combined with vonoprazan and high-dose amoxicillin dual therapy,with that of vonoprazan and high-dose amoxicillin dual therapy.

Eligibility criteria:
inclusion criteria: 1. age 18-65 years old 2. patients with h.pylori infection 3. diagnosed as functional dyspepsia 4. meet the diagnostic criteria of h. pylori cold-heat syndrome in traditional chinese medicine. 5. patients who have not received h. pylori eradication treatment before, or who have failed eradication in the early stage but have not received eradication treatment within six months. 6. volunteer to participate in this experiment and sign the informed consent. exclusion criteria: 1. allergy to research drugs (penicillin allergy, etc.) 2. patients with gastric and duodenal ulcer, pyloric obstruction, esophageal and gastric varices, gastrorrhagia, gastrointestinal mucosa with dysplasia, gastric malignant tumor and other gastrointestinal diseases. 3. patients with severe heart, brain, liver, kidney, hematopoietic system and connective tissue diseases 4. patients who have received h. pylori eradication treatment within six months. 5. antibiotics and bismuth were used 4 weeks before the start of study treatment, and histamine h2 receptor antagonist or ppi was used 2 weeks before the start of study treatment. 6. use adrenocortical hormone, non-steroidal anti-inflammatory drugs or anticoagulants. 7. history of esophageal or gastric surgery 8. pregnant and lactating women